Results add to data suggesting that SVR can be achieved with the combination of daclatasvir (BMS-790052) and asunaprevir (BMS-650032) in HCV genotype 1b patients Study expanded to include alfa/RBV ineligible or intolerant patients Bristol-Myers Squibb Company (NYSE: BMY) announced results from a ten patient sentinel cohort of an ongoing Phase II study in which treatment with a dual, all-oral direct-acting antiviral (DAA) regimen of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052) and the investigational NS3 protease inhibitor asunaprevi...
More...
More...